A novel experimental model of acute hypertriglyceridemia induced by schisandrin B

European Journal of Pharmacology

Volumn 537, Issue 1-3, 2006, Pages 200-204

  Pan, Si Yuan ^a   Dong, Hang ^a   Han, Yi Fan ^b   Li, Wen Yuan ^a   Zhao, Xing Ye ^a   Ko, Kam Ming ^b  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

Author keywords

Fenofibrate; Hypertriglyceridemia; Schisandrin B; Total cholesterol; Triglyceride

Indexed keywords

FENOFIBRATE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SCHISANDRA CHINENSIS EXTRACT; SCHISANDRIN B; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CHEMICAL REACTION KINETICS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FRUIT; HYPERTRIGLYCERIDEMIA; LIPID LIVER LEVEL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCHISANDRACEAE; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTILIPEMIC AGENTS; CYCLOOCTANES; DISEASE MODELS, ANIMAL; HYPERTRIGLYCERIDEMIA; LIGNANS; LIPIDS; LIVER; MALE; MICE; MICE, INBRED ICR; POLYCYCLIC COMPOUNDS; PROCETOFEN;

EID: 33646162647     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.03.001     Document Type: Article

References (22)

1. Blackburn P., Lamarche B., Couillard C., Pascot C., Bergeron N., Prud'homme D., Tremblar A., Bergeron J., Lemieux I., and Despres J.P. Postprandial hyperlipidemia: another correlate of the "hypertriglyceridemic waist" phenotype in men. Atherosclerosis 171 (2003) 327-336
2. Boivin A., and Deshaies Y. Dietary rat models in which the development of hypertriglyceridemia and that of insulin resistance are dissociated. Metabolism 44 (1995) 1540-1547
3. Csaszar A. Hypertriglyceridemia, the coronary heart disease risk marker "solved". Acta Physiol. Hung. 92 (2005) 109-120
4. Chiu P.Y., and Ko K.M. Schisandrin B protects myocardial ischemia-reperfusion injury partly by inducing Hsp25 and Hsp70 expression in rats. Mol. Cell. Biochem. 266 (2004) 139-144
5. Chiu P.Y., Tang M.H., Mak D.H.F., Poon M.K.T., and Ko K.M. Hepatoprotective mechanism of schisandrin B: role of mitochondrial glutathione antioxidant status and heat shock proteins. Free Radic. Biol. Med. 35 (2003) 368-380
6. Curnew G.P. Fenofibrate: a third-generation fibrate lipid-regulating agent. Today's Ther. Trends 12 (1994) 93-101
7. Eaton S., Record C.O., and Bartlett K. Multiple biochemical effects in the pathogenesis of alcoholic fatty liver. Eur. J. Clin. Invest. 27 (1997) 719-722
8. Funatsu T., Kakuta H., Takasu T., Noguchi N., Suzuki M., and Mivata K. Experimental model of postprandial hypertriglyceridemia in sucrose-fed rats and the effectiveness of atorvastatin in the model. Metabolism 52 (2003) 609-615
9. Hamet P. Rat model of familial combined hyperlipidemia as a result of comparative mapping. Physiol. Genomics 17 (2004) 38-47
10. Hofker M.H., van Vlijmen B.J.M., and Havekes L.M. Transgenic mouse models to study the role of APOE in hyperlipidemia and atherosclerosis. Atherosclerosis 137 (1998) 1-11
11. Hokanson J.E., and Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J. Cardiovasc. Risk 3 (1996) 213-219
12. Ip S.P., Poon M.K.T., Wu S.S., Che C.T., Ng K.H., Kong Y.C., and Ko K.M. Effect of schisandrin B on hepatic glutathione antioxidant system in mice: protection against carbon tetrachloride toxicity. Planta Med. 61 (1995) 398-401
13. Khoo K.L., Tan H., Liew Y.M., Deslypere J.P., and Janus E. Lipids and heart disease in Asia. Atherosclerosis 169 (2003) 1-10
14. Klein C.J., Stanek C.S., and Wiles C.E. Overfeeding macronutrients to critically ill adults: metabolic complications. J. Am. Diet. Assoc. 98 (1998) 795-806
15. Ko R.K.M., and Mak D.H.F. Schisandrin B and other dibenzocyclooctadiene lignans. In: Packer L., Halliwell B., and Ong C.N. (Eds). Modern Herbal Medicine: Molecular Basis in Health and Disease Management (2004), Marcel Dekker, New York 289-314
16. Masucci-Magoulas L., Goldberg I.J., Bisgaier C.L., Serajuddin H., Francone O.L., Breslow J.L., and Tall A.R. A mouse model with features of familial combined hyperlipidemia. Science 275 (1997) 391-394
17. Pan S.Y., and Han Y.F. Comparison of the inhibitory efficacy of four belladonna drugs on gastrointestinal movement and cognitive function in food-deprived mice. Pharmacology 72 (2004) 177-183
18. Pan S.Y., Han Y.F., Carlier P.R., Pang Y.P., Mak D.H.F., Lam B.Y.H., and Ko K.M. Schisandrin B protects against tacrine- and bis(7)-tacrine-induced hepatotoxicity and enhances cognitive function in mice. Planta Med. 68 (2002) 217-220
19. Tang M.H., Chiu P.Y., and Ko K.M. Hepatoprotective action of schisandrin B against carbon tetrachloride toxicity was mediated by both enhancement of mitochondrial glutathione status and induction of heat shock proteins in mice. Biofactors 19 (2003) 33-42
20. Tsimihodimos V., Miltiadous G., Daskalopoulou S.S., Mikhailidis D.P., and Elisaf M.S. Fenofibrate: metabolic and pleiotropic effects. Current Vasc. Pharmacol. 3 (2005) 87-98
21. Weinstock P.H., Bisgaier C.L., Aalto-Setälä K., Radner H., Ramakrishnan R., Levak-Frank R., Essenburg A.D., Zechner R., and Breslow J.L. Severe hypertriglyceridemia, reduced high density lipoprotein, and neonatal death in lipoprotein lipase knockout mice. Mild hypertriglyceridemia with impaired very low density lipoprotein clearance in heterozygotes. J. Clin. Invest. 96 (1995) 2555-2568
22. Witztum J.L. Drugs used in the treatment of hyperlipoproteinemias. In: Hardman J.G., and Limbird L.E. (Eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics (1996), McGraw-Hill, New York, NY 875-897